RNAi therapy for hepatitis B virus infection
US10806750B2 · kind B2 · utility
3Cited by
61References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2018 |
| Grant date | Oct 20, 2020 |
| Priority date | — |
| Expiry date | Oct 1, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.